Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Stocktradesmoon Sep. 22 at 2:29 PM

$ABCL HERE WE GO $13’ssss!! Let’s GO!!

0 · Reply

DeMampCamp Sep. 22 at 2:22 PM

$ABCL Shorts trying really hard to keep this away from $13, it's only a matter of time! Let the algos trade until we get closer to the Women's menopause conference!

0 · Reply

Stocktradesmoon Sep. 22 at 1:39 PM

$ABCL Get in NOW!! $12.60’sss heading to $13’sss Fast 💨!! Last CHANCE!! $ABCL gots so much going for it!!

0 · Reply

Ckkung71 Sep. 22 at 1:38 PM

$ABCL Robot algo trades all day again?

0 · Reply

Stocktradesmoon Sep. 22 at 12:20 PM

$ABCL 👀🚨 $15.29-$16.89 this week‼️ GET in NOW here @ $12.67’sss going to $14’sss today!! DON’T MISS OUT!! LARGEST IMS 2026 MENOPAUSE THERAPEUTIC CONVENTION CONFERENCE in a few days!! 🤯 $ABCL 🚨👀 PART 1/2 🧬 ABCL635 — Next Data Disclosure Date Has Been Set 📢 AbCellera has officially announced that it will present Phase 2 efficacy and safety data (Phase 2 Results 12 WEEK DATA 📊 (the 90 DAY’s) for ABCL635 orally at the IMS World Menopause Society meeting on October 1. The key takeaway from this announcement isn’t just;participating in the conference; 🔹 August disclosure → Primarily 4-week topline data 🔹 October 1 → Formal presentation of Phase 2 data on the academic stage In other words, the date for the next data readout on 635 has been clarified. 🎯 Click on this message to see PART 2/2!!

1 · Reply

Jwa68 Sep. 22 at 12:03 PM

$ABCL $GANX $COYA Same story... ABCL will trend higher, COYA will very soon trade close to where ABCL is now, while GANX likely soon trades to where COYA is now. If you are keeping score, both COYA and GANX soon should double. All three companies likely acquired by pharma. COYA will be first to go in my mind, by year end.

1 · Reply

Stocktradesmoon Sep. 22 at 10:49 AM

$ABCL 👀🚨Can’t imagine you plan a Menopause Therapeutic Data Release at the Largest 2026 IMS World Menopause Conference to Share bad results?! ABSOLUTELY 💯 NOT! LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.67’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️ 🚨IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss! Good luck keeping this down!! We are in a BREAK-OUT $17-$23’ss by next WEEK! SMART Money Positioning ahead of the Pipeline. Best 30 minute Conference Call I HAVE EVER LISTENED TOO!!! 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From 10events a day to “ZERO” 🤯 BLACKROCK INC. THE #1 Financial Institution went 15M to 45M $ABCL Shares‼️

3 · Reply

Stocktradesmoon Sep. 22 at 10:46 AM

$ABCL 🚨👀 😮 🤯 Carl is locked in.... we don't have enough shares. He basically laughed off phase3 not being successful... “It's green lights ahead baby”!! His exact words! And now imagine $ABCL with the market cap of $MRNA And of course… well, it keeps going up $ABCL. If the executives and CFO themselves are telling you with their actions what you need to do. Well, the one who catches on does it. On the other hand, and as a reminder, the IPO was in December at $20 and on the first day it closed at $71. (hint..hint) Zero doubt that it will surpass those levels. Spot on man. The next 24 months may be truly epic.

0 · Reply

Stocktradesmoon Sep. 22 at 10:00 AM

$ABCL 🚨Can’t imagine you plan a Menopause Therapeutic Data Release at the Largest 2026 IMS World Menopause Conference to Share bad results?! ABSOLUTELY 💯 NOT! LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.67’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️ 🚨IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss! Good luck keeping this down!! We are in a BREAK-OUT $17-$23’ss by next WEEK! SMART Money Positioning ahead of the Pipeline. Best 30 minute Conference Call I HAVE EVER LISTENED TOO!!! 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From 10events a day to “ZERO” 🤯 BLACKROCK INC. THE #1 Financial Institution went 15M to 45M $ABCL Shares‼️

7 · Reply

Stocktradesmoon Sep. 22 at 9:48 AM

$ABCL 😮 🤯 AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 VANCOUVER, British Columbia-(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil. Details on AbCellera’s oral presentation at IMS are as follows: Title: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms Abstract ID: 16836 Session: Symptoms of Menopause 1 Date and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3 Location: Aruba 1, Windsor Oceânico Hotel & Congress Center 🚨👀AbCellera will present efficacy and safety data from its Phase 2 trial in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS). The abstract can be viewed online here.

0 · Reply

AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause

Sep 16, 2026, 4:05 PM EDT - 5 days ago

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Sep 9, 2026, 2:10 PM EDT - 12 days ago

AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 2, 2026, 4:05 PM EDT - 19 days ago

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

2026-08-25T16:06:05.000Z - 27 days ago

AbCellera rises 17.0%

2026-08-25T14:06:36.000Z - 4 weeks ago

AbCellera rises 10.7%

Aug 13, 2026, 12:05 AM EDT - 5 weeks ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-08-11T20:05:47.000Z - 5 weeks ago

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 5 weeks ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 6 weeks ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 6 weeks ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 6 weeks ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 6 weeks ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 6 weeks ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 6 weeks ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 6 weeks ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 6 weeks ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 6 weeks ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 6 weeks ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 7 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 7 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 2 months ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 3 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 3 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 4 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 5 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 6 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 7 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 8 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 8 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 8 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 9 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Stocktradesmoon Sep. 22 at 2:29 PM

$ABCL HERE WE GO $13’ssss!! Let’s GO!!

0 · Reply

DeMampCamp Sep. 22 at 2:22 PM

$ABCL Shorts trying really hard to keep this away from $13, it's only a matter of time! Let the algos trade until we get closer to the Women's menopause conference!

0 · Reply

Stocktradesmoon Sep. 22 at 1:39 PM

$ABCL Get in NOW!! $12.60’sss heading to $13’sss Fast 💨!! Last CHANCE!! $ABCL gots so much going for it!!

0 · Reply

Ckkung71 Sep. 22 at 1:38 PM

$ABCL Robot algo trades all day again?

0 · Reply

Stocktradesmoon Sep. 22 at 12:20 PM

1 · Reply

Jwa68 Sep. 22 at 12:03 PM

1 · Reply

Stocktradesmoon Sep. 22 at 10:49 AM

3 · Reply

Stocktradesmoon Sep. 22 at 10:46 AM

0 · Reply

Stocktradesmoon Sep. 22 at 10:00 AM

7 · Reply

Stocktradesmoon Sep. 22 at 9:48 AM

0 · Reply

Bastox Sep. 21 at 10:32 PM

$ABCL Breaking News! Moonsludge has changed his name to: Always Wrong. It fits perfectly

0 · Reply

8008track Sep. 21 at 8:33 PM

$ABCL green is green

0 · Reply

Bastox Sep. 21 at 8:10 PM

$ABCL Oh no, Moonlet. How is that you can be so wrong so often??

1 · Reply

Bastox Sep. 21 at 7:57 PM

$ABCL Moon Moron. Wait….wait. You said $13.30’s by the close and you say you’re always right. Can you help us understand?

0 · Reply

Bastox Sep. 21 at 7:39 PM

$ABCL Moonage, wrong again? Are you embarrassed?

0 · Reply

Bastox Sep. 21 at 7:31 PM

$ABCL Moonie! You said $13.30’s by close and you say you’re always right What happened? Could you be wrong? Oh no! Again with the wrong?

0 · Reply

Stocktradesmoon Sep. 21 at 7:16 PM

$ABCL 🚨READ this 👇🏻👇🏻 👀 ‼️

2 · Reply

Bastox Sep. 21 at 7:15 PM

$ABCL StockieMoon ”I have been right all along”. Haha You’re wrong almost every day and will be wrong today.

0 · Reply

Stocktradesmoon Sep. 21 at 6:56 PM

$ABCL I told you ALL WE Would go GREEN!! Now this is your CHANCE to GET IN We are heading Mid $13.55’sss VERY FAST!!💨 I have been Right ALL ALONG…Listen!! We are going to be MUCH HIGHER today by END of DAY and Especially by END of WEEK!! The CHART 📈 is BREAKING-OUT it wants IPO prices $20-$23’ss! We got A lot of GREAT NEWS Out and the Conference Call from Our CEO CARL was a HOMERUN!! It’s a MUST LISTEN!! 🎧 That’s NOT ALL! And Now we got some Announcements of more things to Come! With the Largest IMS MENOPAUSE Convention Conference HAPPENING in a few days we are going NEW 52 WEEK HIGHS‼️ 🚨RUMOR is $ABCL wants $ABVX in a cash and equity deal!!!! That’s a HUGE DEAL…that would send us $25-30’sss OVERNIGHT‼️ What are you waiting for??…to Pay Higher Prices..$ABCL is a gift at these prices all institutions who have bought paid about $25-30 per share!! 🫣 🚨Our Phase II Results were so Impressive‼️ Now 12 Week Data 📊 going to be released in a few days @ Largest IMS Menopause Conference!!

2 · Reply

Stocktradesmoon Sep. 21 at 6:03 PM

$ABCL 🚨Can’t imagine you plan a Menopause Therapeutic Data Release at the Largest 2026 IMS World Menopause Conference to Share bad results?! ABSOLUTELY 💯 NOT! LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.55’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️ 🚨IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss! Good luck keeping this down!! We are in a BREAK-OUT $17-$23’ss by next WEEK! SMART Money Positioning ahead of the Pipeline. Best 30 minute Conference Call I HAVE EVER LISTENED TOO!!! 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From 10events a day to “ZERO” 🤯 BLACKROCK INC. THE #1 Financial Institution went 15M to 45M $ABCL Shares‼️

2 · Reply

Stocktradesmoon Sep. 21 at 5:19 PM

$ABCL LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.55’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️And with all the great NEWS OUT and then we have the IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss!!! Good luck keeping this down!!! We are in a BREAK-OUT $17-$23’sss by next WEEK!!! 🚨$ABCL can’t imagine you plan a menopause therapeutic data release at the 2026 IMS World Menopause conference to share bad results! Q2 13Fs: BlackRock opened a ~3.8M-share position (~$30M), with Man Group and HSBC also starting positions. Inst own 61%Cantor Healthcare Conference on Sep 9 kept it in front of healthcare investors. Smart money positioning ahead of the pipeline. $ABCL 📈 looks better EVERYDAY‼️

1 · Reply

Stocktradesmoon Sep. 21 at 5:15 PM

$ABCL HERE WE GO!! $13’sss LAST Chance! Get in NOW or Regret by this afternoon when we are at $13.30’sss

0 · Reply

Market Cap	3.87B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,425,800
Avg Vol	6,900,506
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	82%
Beta	1.32
Analysts	Strong Sell
Price Target	$17.12